Centre Georges François Leclerc
Dijon, France
53 recruiting
Showing 1–20 of 59 trials
Recruiting
Phase 2
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Other Solid Tumors, AdultFGFR2 Gene Fusion/Rearrangement
Elevar Therapeutics30 enrolled19 locationsNCT07359820
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 3
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Prostate Cancer Metastatic
UNICANCER300 enrolled95 locationsNCT04916613
Recruiting
Phase 3
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence
Cutaneous Squamous Cell Carcinoma (CSCC)
Centre Leon Berard266 enrolled28 locationsNCT06692556
Recruiting
Phase 3
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled34 locationsNCT05581121
Recruiting
Phase 2
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Bristol-Myers Squibb76 enrolled48 locationsNCT06946797
Recruiting
Not Applicable
Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention
Brain Tumor, Pediatric
Institut Claudius Regaud130 enrolled15 locationsNCT06599879
Recruiting
Not Applicable
Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction
Breast CancerCapsular Contracture Associated With Breast Implant
Institut du Cancer de Montpellier - Val d'Aurelle250 enrolled9 locationsNCT04342546
Recruiting
Phase 2
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Ovarian Cancer
ARCAGY/ GINECO GROUP390 enrolled88 locationsNCT05183984
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
ENSAT Stage I Adrenal Cortex CarcinomaENSAT Stage II Adrenal Cortex CarcinomaENSAT Stage III Adrenal Cortex Carcinoma
M.D. Anderson Cancer Center240 enrolled33 locationsNCT03583710
Recruiting
Phase 4
Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud210 enrolled11 locationsNCT07195344
Recruiting
Phase 3
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Brain TumorGlioblastomaGBM+1 more
Ivy Brain Tumor Center450 enrolled95 locationsNCT06388733
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
HER2-negative Breast CancerAdvanced Breast CancerER Positive Breast Cancer+1 more
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
Gustave Roussy, Cancer Campus, Grand Paris162 enrolled6 locationsNCT07001618
Recruiting
Phase 2
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Metastatic/Locally Advanced Non-Small-Cell Lung CancerMetastatic/Locally Pancreatic Ductal Adenocarcinoma
Gustave Roussy, Cancer Campus, Grand Paris60 enrolled6 locationsNCT07483983
Recruiting
Phase 3
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Glioblastoma
Centre Oscar Lambret486 enrolled19 locationsNCT03663725
Recruiting
Phase 2
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Centre Hospitalier Universitaire de Besancon105 enrolled14 locationsNCT05528952